论文部分内容阅读
Docetaxel and/or zoledronic acid for hormone-na(i)ve prostate cancer: First overall survival results
【作 者】
:
【机 构】
:
University of Warwick,Coventry, United Kingdom MR
【出 处】
:
2015年临床肿瘤学新进展学术研讨会
【发表日期】
:
2015年3期
其他文献
Efficacy, safety and predictive biomarker results from a randomized phase Ⅱ study comparing MPDL3280
会议
Elective versus therapeutic neck dissection in the clinically node negative early oral cancer: A ran
会议
Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Me
会议
Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Prelim
会议
Phase Ⅱ/Ⅱ study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung c
会议
Final overall survival (OS) results of the phase Ⅲ PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis)
会议
Randomized phase Ⅲ trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels
会议
Randomized phase Ⅱ, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (
会议